SECURITIES AND EXCHANGE COMMISSION |
Washington, D.C. 20549 |
SCHEDULE 13G |
(Rule 13d-102) |
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT |
TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED |
PURSUANT TO RULE 13d-2(b) |
(Amendment No. )1 |
SpringWorks Therapeutics, Inc. |
(Name of Issuer) |
Common Stock, $0.0001 par value |
(Title of Class of Securities) |
85205L107 |
(CUSIP Number) |
December 31, 2019 |
(Date of Event Which Requires Filing of this Statement) |
1. | NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (VOLUNTARY) Pfizer Inc. | |||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) [ ] (b) [ ] | ||
3. | SEC USE ONLY | |||
4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | |||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 4,017,245 | ||
6. | SHARED VOTING POWER 576,602 | |||
7. | SOLE DISPOSITIVE POWER 4,017,245 | |||
8. | SHARED DISPOSITIVE POWER 576,602 | |||
9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,593,847* | |||
10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | [ ] | ||
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.7%** | |||
12. | TYPE OF REPORTING PERSON CO |
1. | NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (VOLUNTARY) Pfizer Ventures (US) LLC | |||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) [ ] (b) [ ] | ||
3. | SEC USE ONLY | |||
4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | |||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER -0- | ||
6. | SHARED VOTING POWER 576,602 | |||
7. | SOLE DISPOSITIVE POWER -0- | |||
8. | SHARED DISPOSITIVE POWER 576,602 | |||
9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 576,602* | |||
10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | [ ] | ||
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 1.3%** | |||
12. | TYPE OF REPORTING PERSON OO |
ITEM 1(a) | NAME OF ISSUER: |
SpringWorks Therapeutics, Inc. | |
ITEM 1(b) | ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES: |
100 Washington Boulevard, Stamford, CT 06902 | |
ITEM 2(a) | NAME OF PERSON FILING: |
Pfizer Inc. (“Pfizer”) Pfizer Ventures (US) LLC (“PVUS”) PVUS is a wholly-owned subsidiary of Pfizer. The Joint Filing Agreement between Pfizer and PVUS is filed herewith as Exhibit 99.1. | |
ITEM 2(b) | ADDRESS OF PRINCIPAL BUSINESS OFFICE: |
Pfizer and PVUS: 235 East 42nd Street, New York, NY 10017 | |
ITEM 2(c) | CITIZENSHIP: |
Pfizer and PVUS: Delaware | |
ITEM 2(d) | TITLE OF CLASS OF SECURITIES: |
Common Stock, $0.0001 par value | |
ITEM 2(e) | CUSIP NUMBER: |
85205L107 | |
ITEM 3 | STATEMENTS FILED PURSUANT TO RULES 13D-1(B) OR 13D-2(B) OR (C): |
Not applicable. |
ITEM 4 | OWNERSHIP: | |||
The information requested in this item is incorporated herein by reference to the cover pages to this Schedule 13G. | ||||
ITEM 5 | OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS: | |||
Not applicable. | ||||
ITEM 6 | OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON: | |||
Not applicable. | ||||
ITEM 7 | IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT COMPANY: | |||
Not applicable. |
ITEM 8 | IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP: |
Not applicable. | |
ITEM 9 | NOTICE OF DISSOLUTION OF GROUP: |
Not applicable. | |
ITEM 10 | CERTIFICATION: |
Not applicable. |
99.1 | Joint Filing Agreement, dated as of February 14, 2020, by and between Pfizer and PVUS. |
PFIZER INC. | ||
By: | /s/ Susan Grant | |
Name: | Susan Grant | |
Title: | Assistant Secretary | |
PFIZER VENTURES (US) LLC | ||
By: | /s/ Susan Grant | |
Name: | Susan Grant | |
Title: | Secretary |
PFIZER INC. | ||
By: | /s/ Susan Grant | |
Name: | Susan Grant | |
Title: | Assistant Secretary | |
PFIZER VENTURES (US) LLC | ||
By: | /s/ Susan Grant | |
Name: | Susan Grant | |
Title: | Secretary |